Showing 2221-2230 of 9396 results for "".
- Barzolvolimab Responses Persist After Treatment in Selected Chronic Urticaria Patientshttps://practicaldermatology.com/news/barzolvolimab-responses-persist-after-treatment-in-selected-chronic-urticaria-patients/2488679/Nearly 7 in 10 evaluable patients with antihistamine-refractory chronic spontaneous urticaria (CSU) who achieved well-controlled disease after a year of barzolvolimab maintained control 24 weeks later, according to a post hoc analysis of a phase 2 trial presented at the 2026 Fall Clinical Dermato
- Hyperpigmentation Review Examines Treatment Strategies and Evidence Gaps in Skin of Colorhttps://practicaldermatology.com/news/hyperpigmentation-review-examines-treatment-strategies-and-evidence-gaps-in-skin-of-color/2488677/A literature review presented at the 2026 Fall Clinical Dermatology Conference examined mechanisms and treatment strategies for hyperpigmentation disorders, emphasizing persistent gaps in evidence involving patients with skin of color. Susan Taylor, MD, of the University of Pennsylvania, a
- Pediatric Nemolizumab Study Reports Improvements in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/pediatric-nemolizumab-study-reports-improvements-in-atopic-dermatitis-through-52-weeks/2488676/Weight-based nemolizumab administered with topical therapy was associated with improvements in skin lesions and itch in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to phase 2 findings presented at the 2026 Fall Clinical Dermatology Conference. Lawr
- Switching From Dupilumab to Upadacitinib Associated With No Skin Flares in Atopic Dermatitis Analysishttps://practicaldermatology.com/news/switching-from-dupilumab-to-upadacitinib-associated-with-few-flares-in-atopic-dermatitis-analysis/2488672/Patients with moderate-to-severe atopic dermatitis (AD) who switched from dupilumab to upadacitinib monotherapy following inadequate treatment response experienced no observed skin lesion flares and infrequent itch flares over 16 weeks, according to a post hoc analysis pres
- Upadacitinib Shows Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitishttps://practicaldermatology.com/news/upadacitinib-shows-earlier-skin-barrier-restoration-than-dupilumab-in-atopic-dermatitis/2488646/A biomarker analysis from the head-to-head Level Up study found that upadacitinib produced early molecular and histologic changes consistent with restoration of the skin barrier in adults with moderate-to-severe atopic dermatitis (AD), with broader changes than dupilumab in the study’s optional b
- FDA Approves Remibrutinib as First Treatment for Symptomatic Dermographismhttps://practicaldermatology.com/news/fda-approves-remibrutinib-as-first-treatment-for-symptomatic-dermographism/2488642/The FDA has approved Rhapsido (remibrutinib; Novartis) for adults with symptomatic dermographism (SD) whose disease is inadequately controlled with H1 antihistamines, according to an October 7 announcement from Novartis. The approval makes remibrutinib the first FDA-approved treatment spec
- Zasocitinib Outperforms Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trialhttps://practicaldermatology.com/news/zasocitinib-outperforms-deucravacitinib-in-phase-3-head-to-head-psoriasis-trial/2488633/Investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) demonstrated superior skin clearance compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis, according to phase 3 data presented at the European Academy of Dermatology & Venereology (EADV)
- Acrotech Brings Difamilast 1% Ointment for Atopic Dermatitis to UShttps://practicaldermatology.com/news/acrotech-brings-difamilast-1-ointment-for-atopic-dermatitis-to-us/2488630/Acrotech Biopharma Inc. announced the United States launch of ADQUEY (difamilast 1%) ointment, a nonsteroidal topical treatment for mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged 2 years and older. Difamilast was originally developed by Otsuka Pharmaceutical
- Environmental Exposures, Skin Barrier Care Take Focus in Pediatric AD Consensushttps://practicaldermatology.com/news/environmental-exposures-skin-barrier-care-take-focus-in-pediatric-ad-consensus/2488624/Environmental exposures early in childhood that affect the skin barrier may contribute to the development of atopic dermatitis, and impact its severity, according to a new expert consensus published in the Journal of Drugs in Dermatology. The SAIGE III report examined current evid
- Dr. Shawn Kwatra Analyzes ADtouch Data on Hand and Foot Atopic Dermatitishttps://practicaldermatology.com/news/dr-shawn-kwatra-analyzes-adtouch-data-on-hand-and-foot-atopic-dermatitis/2488634/New Phase 3b ADtouch data for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas, according to study investigator Shawn Kwatra, MD.